Navigation Links
AcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain in Major Open Abdominal Surgery Patients
Date:3/4/2013

hase 3 clinical trials and a New Drug Application submission is planned for the third quarter of 2013. AcelRx recently completed enrollment in a Phase 2 study for ARX-04, a sufentanil formulation for the treatment of moderate-to-severe acute pain, funded through a grant from U.S. Army Medical Research and Materiel Command, and top-line results are expected in the second quarter of 2013.  The company has two additional pain treatment product candidates, ARX-02 and ARX-03, which have completed Phase 2 clinical development.  For additional information about AcelRx's clinical programs please visit www.acelrx.com.

Forward Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to the process and timing of anticipated future clinical development of AcelRx Pharmaceuticals' product candidates, including the release of sufentanil NanoTab PCA System top-line clinical trial data, the release and anticipated timing of additional NanoTab System clinical trial data, the potential submission of an NDA for NanoTab System and the timing thereof, therapeutic and commercial potential of NanoTab System and the anticipated timing and therapeutic and commercial potential of other AcelRx Pharmaceuticals' product candidates.  These forward-looking statements are based on AcelRx Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties.  AcelRx Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to: the ability of AcelRx Pharmaceuticals to successfully complete the clinical trials for the sufentanil NanoTab System, that fact that subsequent analyses of the top-line data may lead to different (including less favorable) interpretations of t
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences
2. AcelRx Pharmaceuticals Provides Clinical Trial Updates
3. AcelRx Appoints Adrian Adams to Board of Directors as Chairman
4. AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
5. AcelRx Pharmaceuticals Announces Proposed Public Offering Of Common Stock
6. AcelRx Pharmaceuticals to Present at the Piper Jaffray 24th Annual Healthcare Conference
7. AcelRx Announces Achievement of the Primary End-Point in Phase 3 Comparative Study Involving the Sufentanil NanoTab PCA System and Plans to Hold a Conference Call and Webcast Tomorrow to Discuss Top-Line Results
8. AcelRx Pharmaceuticals Reports Third Quarter 2012 Financial Results
9. AcelRx Pharmaceuticals Doses the First Patients in ARX-04 Phase 2 Clinical Study
10. AcelRx Pharmaceuticals to Hold Third Quarter 2012 Financial Results Conference Call and Webcast on November 6, 2012
11. AcelRx Pharmaceuticals Hires Mike A. Royal, M.D. as Chief, Clinical Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , Aug. 3, 2015  Sage Analytics ( www.sageanalytics.com ... laboratory-quality cannabis potency measurement systems, announced its sponsorship of ... Cruise Fundraiser. A limited number of tickets are available ... help a great cause while enjoying an open bar, ... around the San Francisco Bay at sunset. ...
(Date:8/3/2015)... , Aug. 3, 2015  Depomed, Inc. (NASDAQ: ... on Horizon Pharma plc,s (NASDAQ: HZNP ) ("Horizon") ... of Directors ("Depomed Board") set a record date to ... The Depomed Board will review the ... is received today and contains the information required under ...
(Date:8/3/2015)... YORK , August 3, 2015 ... published by Persistence Market Research "Global Market Study ... to Witness Highest Growth by 2022", the ... US$15 Bn by the end of 2015 and is ... from 2015 to 2022, to account for US$23.7 ...
Breaking Medicine Technology:Sage Analytics Sponsors California Cannabis Industry Association Bay Area Cruise FUNdraiser 2Depomed Comments on Horizon Pharma Announcement 2Depomed Comments on Horizon Pharma Announcement 3Depomed Comments on Horizon Pharma Announcement 4Depomed Comments on Horizon Pharma Announcement 5Depomed Comments on Horizon Pharma Announcement 6Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 2Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 3Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 4
... development portfolio building on lead product ... Phase 2 trial for onychomycosis, WELLESLEY HILLS, Mass., ... announced that it has,exercised the option it acquired in ... uses of pexiganan, a novel, small peptide,anti-infective for treatment ...
... BOULDER, Colo., Oct. 3 Tapestry,Pharmaceuticals, Inc. (Nasdaq: ... 2 open- label, multi-center study of TPI 287 in ... 2 trial exploring the,activity of TPI 287 in various ... year in advanced hormone refractory prostate cancer. "Currently ...
Cached Medicine Technology:MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera 2MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera 3MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera 4MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera 5MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera 6Tapestry Initiates Phase 2 Trial of TPI 287 for the Treatment of Advanced Pancreatic Cancer 2Tapestry Initiates Phase 2 Trial of TPI 287 for the Treatment of Advanced Pancreatic Cancer 3Tapestry Initiates Phase 2 Trial of TPI 287 for the Treatment of Advanced Pancreatic Cancer 4Tapestry Initiates Phase 2 Trial of TPI 287 for the Treatment of Advanced Pancreatic Cancer 5
(Date:8/4/2015)... ... August 04, 2015 , ... ... in which the physician is board-certified is increasingly influential in their choice of ... , The 2015 ASDS Consumer Survey on Cosmetic Dermatologic Procedures reflects overall consumer ...
(Date:8/4/2015)... ... 04, 2015 , ... Mercy Health (formerly Catholic Health Partners) – a Catholic healthcare ministry serving ... Be Well videos to preparing high school athletes for fall sports. , In a concise ... as:, , What steps to take to help prevent injuries , ...
(Date:8/4/2015)... , ... August 04, 2015 , ... More than 700 ... renewed their wedding vows on Friday, July 24th. Chaplains Shawn Kafader and Richard ... each other. Following the ceremony was a reception, with music by the Moonlight ...
(Date:8/4/2015)... ... August 04, 2015 , ... The goal of looking younger – ... for invasive surgery to achieve this ideal is not. But minimally invasive procedures such ... the high cost or lengthy recovery time, according to Valerie Goldburt, MD, PhD ...
(Date:8/4/2015)... ... August 04, 2015 , ... In ... filed against Johnson & Johnson report that a new location for pretrial proceedings ... regular news updates and cancer warning information at their website, the Talcum Powder ...
Breaking Medicine News(10 mins):Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 2Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 3Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 4Health News:Mercy Health Video Provides Helpful Information for High School Athletes 2Health News:Couples Renew Vows at Friendship Village of Schaumburg 2Health News:Considering fillers, tighteners or laser resurfacing? 2Health News:Considering fillers, tighteners or laser resurfacing? 3Health News:Considering fillers, tighteners or laser resurfacing? 4Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 2Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 3Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 4
... Oct. 28 /Xinhua-PRNewswire-FirstCall/ -- China Sky One,Medical, ... Company") (Nasdaq: CSKI ), a,leading fully ... People,s Republic of China ("PRC"), announced today ... a proprietary breast drug from,Harbin Medical University ...
... Contribute to Blood Vessels, Healthy ... Ability to Relax, ... component of soy may enhance the function of arteries,in stroke patients, and ... and Prevention, heart disease is the,nation,s number one killer while stroke is ...
... Oct. 28 The Los Angeles Shambhala Center,presents a public ... the weekend, Oct 30 and November 1st and 2nd., ... Japan will,appear for the first time in Los Angeles at ... at Figueroa and Colorado Blvd.,in Eagle Rock., On Thursday, ...
... WellSpring Pharmaceutical,Corporation, a growing North American-based pharmaceutical manufacturer,today ... Operating Officer.,Formerly, Ms. Shusko held the position of ... 2000. In her new role as COO, Ms. ... of oversight,to operations with an initial focus on ...
... /PRNewswire-FirstCall/ - Response Biomedical,Corporation (TSX: RBM, OTCBB: RPBIF) ... initial closing of the financing announced on October,14, ... gross proceeds of $4.66,million. The closing involved a ... a price of $0.15 for each unit. Each ...
... for internet-based public reporting to help consumers ... WASHINGTON Oct. 28 To support consumer,engagement ... Quality Forum,(NQF) endorsed guidelines for consumer-focused, internet-based ... to present,information about hospital quality in an ...
Cached Medicine News:Health News:China Sky One Medical, Inc. Acquires Drug to Treat Breast Lesions 2Health News:China Sky One Medical, Inc. Acquires Drug to Treat Breast Lesions 3Health News:Study Shows How Soy Compound Lowers Blood Pressure and Stroke Risk 2Health News:Renowned Kyudo (Zen archery) Master Kanjuro Shibata Sensei to Present in L.A. 2Health News:WellSpring Pharmaceutical Corp. Names Wendy Shusko as New Chief Operating Officer 2Health News:Response Biomedical Completes Initial Closing of an expected $5.0 Million Financing 2Health News:Response Biomedical Completes Initial Closing of an expected $5.0 Million Financing 3Health News:Response Biomedical Completes Initial Closing of an expected $5.0 Million Financing 4Health News:NQF Endorses Guidelines for Consumer-Focused Public Reporting 2Health News:NQF Endorses Guidelines for Consumer-Focused Public Reporting 3Health News:NQF Endorses Guidelines for Consumer-Focused Public Reporting 4Health News:NQF Endorses Guidelines for Consumer-Focused Public Reporting 5
The Tri-Flex II system is a second generation healthcare patient support system that has the benefits of the original Tri-Flex system and multiple, updated support functions for increased comfort and...
... designed to make your bariatric patients feel comfortable ... them. , ,When caring for this population, ... in bed, turning, sitting, standing can be ... Care ES bed offers features to make these ...
... dignity. A single solution., ,Hill-Rom engineers ... added safety where its needed. Its long ... protect the caregiver and patient from injury, ... just like other TotalCare® beds, but its ...
... We offer a wide selection of solutions ... therapy use. The sterile water for inhalation ... in plastic pour bottles in 500 and ... prefilled nebulizer kits or can be used ...
Medicine Products: